Merck & Company, Inc. vs TransMedics Group, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and TransMedics Group, Inc. (TMDX) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
TransMedics Group, Inc. narrowly edges Merck & Company, Inc. on Q·Score (7.5 vs 7 out of 10), led by Quality (9.3 vs 7.7) and Valuation (7.9 vs 6.7). Merck & Company, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for TMDX (+48.2%) than for MRK (+13.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
High-quality business with 45% return on equity and 27% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs TMDX: which stock scores better overall?
Based on Q·Score, TransMedics Group, Inc. (TMDX) scores 7.5/10 versus Merck & Company, Inc. (MRK) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or TMDX?
TransMedics Group, Inc. (TMDX) scores higher on Growth (6.6/10 vs 6.2/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while TransMedics Group, Inc. reports (21.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or TMDX more attractively valued?
TransMedics Group, Inc. (TMDX) scores higher on Valuation (7.9/10 vs 6.7/10). MRK trades at 11.9× P/E versus TMDX at 23.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs TMDX?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 9 analysts covering TMDX with a consensus target of $116.78. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or TMDX?
TransMedics Group, Inc. (TMDX) scores higher on Quality (9.3/10 vs 7.7/10). Net profit margin: MRK at 13.6%, TMDX at 27.0%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or TMDX?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 6.2/10). Market beta: MRK at 0.22, TMDX at 1.88. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and TMDX?
Merck & Company, Inc. (MRK) has a market capitalisation of $281.2B, while TransMedics Group, Inc. (TMDX) has a market cap of $2.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or TMDX pay dividends?
MRK pays a dividend yield of 2.95%, while TMDX does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →